REGENERON PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
REGENERON PHARMACEUTICALS, INC. (REGN) reported Capital Expenditures Incurred but Not yet Paid of $182.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $19.90M, a 1.49% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $162.50M, a 53.45% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $1.90M, a 96.70% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $50.80M.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $75.40M, a 6.50% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $70.80M, a 5.35% decline from fiscal 2021.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $74.80M, a 10.53% decline from fiscal 2020.
- REGENERON PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2020 was $83.60M, a 37.47% decline from fiscal 2019.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 3 month as first filed | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 6 month as first filed | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $182.40M 10-Q · filed 2026-07-30 | $184.30M derived: sum of 3 quarters · filed 2026-07-30 | $235.10M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $162.50M 10-Q · filed 2026-04-29 | $164.40M derived: sum of 2 quarters · filed 2026-07-30 | $215.20M derived: sum of 3 quarters · filed 2026-07-30 | $235.40M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | $1.90M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | $52.70M derived: sum of 2 quarters · filed 2026-07-30 | $72.90M derived: sum of 3 quarters · filed 2026-07-30 | $178.80M 10-Q · filed 2026-07-30 | ||
| 2025-09-30 | $50.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $71.00M derived: sum of 2 quarters · filed 2026-07-30 | $176.90M 10-Q · filed 2025-10-28 | $234.50M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $20.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $126.10M 10-Q · filed 2026-07-30 | $183.70M derived: sum of 3 quarters · filed 2026-07-30 | $126.10M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $105.90M 10-Q · filed 2026-04-29 | $163.50M derived: sum of 2 quarters · filed 2026-07-30 | $105.90M derived: sum of 3 quarters · filed 2026-07-30 | $149.50M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2024-12-31 | $57.60M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | $0.00 derived: sum of 2 quarters · filed 2026-07-30 | $43.60M derived: sum of 3 quarters · filed 2026-07-30 | $151.60M 10-Q · filed 2026-07-30 | ||
| 2024-09-30 | -$57.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$14.00M derived: sum of 2 quarters · filed 2026-04-29 | $94.00M 10-Q · filed 2025-10-28 | $70.50M derived: sum of 4 quarters · filed 2026-04-29 | ||
| 2024-06-30 | $43.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-29 | $151.60M 10-Q · filed 2026-04-29 | $112.60M 10-Q · filed 2024-08-01 | $128.10M derived: sum of 3 quarters · filed 2026-04-29 | $151.60M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-03-31 | $108.00M 10-Q · filed 2025-04-29 | $84.50M derived: sum of 2 quarters · filed 2026-02-04 | $108.00M derived: sum of 3 quarters · filed 2026-02-04 | $93.10M derived: sum of 4 quarters · filed 2026-02-04 | ||
| 2023-12-31 | -$23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $0.00 derived: sum of 2 quarters · filed 2026-02-04 | -$14.90M derived: sum of 3 quarters · filed 2026-02-04 | $75.40M 10-K · filed 2026-02-04 | ||
| 2023-09-30 | $23.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $8.60M derived: sum of 2 quarters · filed 2025-04-29 | $98.90M 10-Q · filed 2024-10-31 | $86.60M derived: sum of 4 quarters · filed 2025-04-29 | ||
| 2023-06-30 | -$14.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-29 | $75.40M 10-Q · filed 2025-04-29 | $107.50M 10-Q · filed 2023-08-03 | $63.10M derived: sum of 3 quarters · filed 2025-04-29 | $146.20M derived: sum of 4 quarters · filed 2025-04-29 | |
| 2023-03-31 | $90.30M 10-Q · filed 2024-05-02 | $78.00M derived: sum of 2 quarters · filed 2025-02-05 | $161.10M derived: sum of 3 quarters · filed 2025-02-05 | $162.30M derived: sum of 4 quarters · filed 2025-02-05 | ||
| 2022-12-31 | -$12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $70.80M derived: sum of 2 quarters · filed 2025-02-05 | $72.00M derived: sum of 3 quarters · filed 2025-02-05 | $70.80M 10-K · filed 2025-02-05 | ||
| 2022-09-30 | $83.10M 10-Q · filed 2022-11-03 | $84.30M derived: sum of 2 quarters · filed 2023-08-03 | $83.10M 10-Q · filed 2023-11-02 | $239.80M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $81.90M 10-Q · filed 2023-08-03 | $156.70M derived: sum of 3 quarters · filed 2023-08-03 | $133.40M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | $80.70M 10-Q · filed 2023-05-04 | $155.50M derived: sum of 2 quarters · filed 2023-05-04 | $132.20M derived: sum of 3 quarters · filed 2023-05-04 | $150.80M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $74.80M 10-Q · filed 2022-11-03 | $51.50M derived: sum of 2 quarters · filed 2022-11-03 | $70.10M derived: sum of 3 quarters · filed 2022-11-03 | $74.80M 10-K · filed 2024-02-05 | ||
| 2021-09-30 | -$23.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$4.70M derived: sum of 2 quarters · filed 2022-11-03 | $70.10M 10-Q · filed 2022-11-03 | $53.30M derived: sum of 4 quarters · filed 2023-02-06 | ||
| 2021-06-30 | $18.60M derived: 10-Q 6 month − 10-K 3 month · filed 2022-08-03 | $93.40M 10-Q · filed 2022-08-03 | $76.60M derived: sum of 3 quarters · filed 2023-02-06 | $89.60M derived: sum of 4 quarters · filed 2023-02-06 | ||
| 2021-03-31 | $74.80M 10-K · filed 2023-02-06 | $75.60M 10-Q · filed 2021-05-06 | $58.00M derived: sum of 2 quarters · filed 2023-02-06 | $71.00M derived: sum of 3 quarters · filed 2023-02-06 | $85.80M derived: sum of 4 quarters · filed 2023-02-06 | |
| 2020-12-31 | -$16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | -$3.80M derived: sum of 2 quarters · filed 2023-02-06 | $11.00M derived: sum of 3 quarters · filed 2023-02-06 | $83.60M 10-K · filed 2023-02-06 | ||
| 2020-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $27.80M derived: sum of 2 quarters · filed 2021-11-04 | $100.40M 10-Q · filed 2021-11-04 | $133.60M derived: sum of 4 quarters · filed 2022-02-07 | ||
| 2020-06-30 | $14.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $87.40M 10-Q · filed 2021-08-05 | $120.60M derived: sum of 3 quarters · filed 2022-02-07 | |||
| 2020-03-31 | $72.60M 10-Q · filed 2021-05-06 | $105.80M derived: sum of 2 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $33.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $133.70M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $100.50M 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $54.50M 10-K · filed 2021-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |